Vectura Group plc today announces an unaudited 2019 pre-close trading update. The Group expects revenue and Adjusted EBITDA to be at least in line with Board expectations. Vectura will report its preliminary results for the year ended 31st December 2019 on Tuesday 17th March 2020.
Will Downie, Chief Executive Officer of Vectura, commented: “The base business continued to perform well, trading in-line with expectations for 2019. Both the recent re-filing of generic Advair and the US Jury verdict in our favour in May 2019, in the GSK litigation, offer the potential for significant value. As Vectura transitions in 2020 to a more services focused model, related new business deals will begin to bring the future shape of the company into focus. This is an exciting time for the Group.”
For the full RNS update, please click here.
Attendance at 38th Annual J.P. Morgan Healthcare Conference
Vectura is attending the 38th Annual J.P. Morgan Healthcare Conference, from 13th to 16th January in San Francisco, California. Will Downie, CEO, will give a presentation at 10.00 am PT on Thursday 16th January. The live presentation will be webcast and may be accessed here.